FFA
TRVI icon

Farther Finance Advisors’s Trevi Therapeutics TRVI Stock Holding History

Farther Finance Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$132K Hold
9,226
– – ﹤0.01% 2631
2026
Q2 		$172K Sell
9,226
-17
-0.2% -$247 ﹤0.01% 2362
2026
Q1 		$107K Sell
9,243
-27
-0.3% -$302 ﹤0.01% 2464
2025
Q4 		$116K Buy
9,270
+432
+5% +$4.99K ﹤0.01% 2245
2025
Q3 		$80.9K Hold
8,838
– – ﹤0.01% 2164
2025
Q2 		$48.3K Buy
8,838
+8,783
+15,969% +$54.6K ﹤0.01% 2150
2025
Q1 		$331 Hold
55
– – ﹤0.01% 3853
2024
Q4 		$227 Hold
55
– – ﹤0.01% 3630
2024
Q3 		$184 Hold
55
– – ﹤0.01% 3672
2024
Q2 		$159 Hold
55
– – ﹤0.01% 3527
2024
Q1 		$185 Buy
+55
New +$123 ﹤0.01% 3287

Other funds holding TRVI

CD
Chapin Davis Baltimore, Maryland $520M AUM 117.57% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Farther Finance Advisors's TRVI Position: Q3 2026 in Review

Farther Finance Advisors held its Trevi Therapeutics (TRVI) position steady in Q3 2026 at 9,226 shares worth $132K. The position accounts for ﹤0.01% of the portfolio, ranked #2631.

Farther Finance Advisors first reported a position in TRVI in Q1 2024 and has held it in 11 quarters since. The position peaked at $172K in Q2 2026. 5 funds tracked by Wall St. Rank hold TRVI as of Q3 2026.

  • Farther Finance Advisors held 9,226 shares of Trevi Therapeutics worth $132K as of Q3 2026.
  • Farther Finance Advisors left its Trevi Therapeutics share count unchanged in Q3 2026.
  • Trevi Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #2631 holding.
  • Farther Finance Advisors first reported a position in Trevi Therapeutics in Q1 2024 and has held it in 11 quarters since.
  • Farther Finance Advisors's Trevi Therapeutics position peaked at $172K in Q2 2026.
  • 5 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.